The shareholders have been actively engaged in XNK Therapeutics since the start in 2012, each contributing with their unique competence as well as investing their own money. Despite limited equity investments, the company has taken its leading investigational drug candidate, CellProtect, to Phase II. To accelerate the development of CellProtect, XNK Therapeutics has decided to launch a financing round in XNK Therapeutics.
July 1, 2021 Non RegulatoryXNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma
June 29, 2021 Non RegulatoryReport from Annual General Meeting in XNK Therapeutics AB (publ)
June 1, 2021 Non RegulatoryNotice convening a general meeting